MAZE
Maze Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report0 of 4 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.81%
vs ±16.0% implied · ×0.05
shaded = implied · ▲▼ = realized
No thesis.
Maze Therapeutics, Inc.
31.42
−0.51 · −1.60%
post 31.10 −1.02%
Linked news
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Frazier Life Sciences ManagementFrazier Life Sciences | $150.2M | 8.58% | +10.20% | |
| 2 | TRV GP IVTRV GP IV | $133.5M | 7.63% | 0.00% | |
| 3 | Arch VentureArch Venture | $123.0M | 7.03% | 0.00% | |
| 4 | Deep Track CapitalDeep Track Capital | $111.4M | 6.37% | +7.33% | |
| 5 | BlackRockBlackRockindex-like | $104.5M | 5.97% | +36.27% | |
| 6 | Jupiter TopcoJupiter Topco | $101.8M | 5.82% | — | |
| 7 | T. Rowe Price Investment ManagementT. Rowe Price | $77.7M | 4.44% | new | |
| 8 | Logos Global ManagementLogos Global | $57.7M | 3.30% | +56.68% | |
| 9 | Vanguard Capital ManagementVanguardindex-like | $53.1M | 3.03% | +23.86% | |
| 10 | AH Capital ManagementAH Capital Management | $50.8M | 2.90% | 0.00% | |
| 11 | VR AdviserVR Adviser | $47.8M | 2.73% | 0.00% | |
| 12 | AlphabetAlphabet | $41.4M | 2.37% | 0.00% | |
| 13 | BraidwellBraidwell | $34.0M | 1.94% | new | |
| 14 | Farallon Capital ManagementFarallon | $33.1M | 1.89% | new | |
| 15 | FMRFMR | $31.5M | 1.80% | +22.30% | |
| 16 | General Catalyst Group ManagementGeneral Catalyst | $30.9M | 1.77% | 0.00% | |
| 17 | State StreetState Streetindex-like | $29.8M | 1.70% | +56.67% | |
| 18 | Driehaus Capital ManagementDriehaus | $28.5M | 1.63% | +50.10% | |
| 19 | TRV GP VTRV GP V | $28.4M | 1.62% | 0.00% | |
| 20 | JPMorgan ChaseJPMorgan Chase | $28.0M | 1.60% | new | |
| 21 | Marshall WaceMarshall Wace | $27.3M | 1.56% | +194.42% | |
| 22 | Citadel AdvisorsCitadel | $26.1M | 1.49% | +8.11% | |
| 23 | Geode Capital ManagementGeodeindex-like | $25.6M | 1.46% | +43.02% | |
| 24 | Casdin CapitalCasdin Capital | $25.2M | 1.44% | +11.20% | |
| 25 | Arrowpoint Asset ManagementArrowpoint | $22.9M | 1.31% | 0.00% |
161 managers report $1.7B of Maze Therapeutics on form 13F for the quarter ended Jun 30 '26. 24 of them hold 80% of it; Frazier Life Sciences is largest at 8.58%.
Expected move
Inputs8Q avg ±7.3%·×1.60·rich
straddle ±14.6%
spot 31.48exp Nov 20ATM strike 30ATM straddle 5.40IV 89%